Pharming's Leniolisib Shows Promise in Broader PID Population…

Event summary

Pharming's Phase II trial of leniolisib in PIDs with immune dysregulation showed positive topline data, accepted as a late-breaking abstract at ESID 2026.
The trial demonstrated a 26.4% mean reduction in spleen volume and improvements in lymphoproliferative disease across 13 patients.
Pharming expects to report Phase II results for leniolisib in CVID patients in Q4 2026.
Leniolisib is already approved for APDS in multiple countries but is not yet established for other PIDs.

The big picture

Pharming's positive Phase II data for leniolisib in PIDs with immune dysregulation suggests the drug could expand beyond its current approval for APDS. This move aligns with broader industry trends of repurposing existing drugs for rare disease indications, potentially unlocking significant commercial value. The upcoming Q4 2026 results for CVID will be critical in determining the next steps for regulatory approval and market entry.

What we're watching

Regulatory Pathway: Whether the Phase II results will support a registrational study in the broader CVID population.
Market Expansion: The potential to address a larger patient population beyond APDS, significantly increasing leniolisib's market opportunity.
Competitive Dynamics: How Pharming's progress with leniolisib positions it against other companies developing treatments for PIDs with immune dysregulation.